CGEN
Undervalued by 8.8% based on the discounted cash flow analysis.
Market cap | $238.26 Million |
---|---|
Enterprise Value | $141.34 Million |
Dividend Yield | $0.0 (0.0%) |
Earnings per Share | $-0.39 |
Beta | 2.06 |
Outstanding Shares | 89,237,465 |
Avg 30 Day Volume | 802,839 |
Return on Equity | - |
---|---|
Return on Assets | - |
Return on Invested Capital | - |
P/E Ratio | -7.08 |
---|---|
PEG | 190.47 |
Price to Sales | - |
Price to Book Ratio | 2.54 |
Enterprise Value to Revenue | 23.56 |
Enterprise Value to EBIT | -4.07 |
Enterprise Value to Net Income | -5 |
Total Debt to Enterprise | 0 |
Debt to Equity | 0 |
No data
No data
Compugen is a clinical-stage therapeutic discovery and development company utilizing its broadly applicable, predictive computational discovery platforms to identify novel drug targets and develop therapeutics in the field of cancer immu...